- Recent/Demonstration Projects: PROUD demonstration study, showing 86 percent risk reduction among gay men in the UK. You can watch a video documentary of the PROUD study here. From September 2017, PrEP will be provided via NHS England to an estimated 10,000 participants in a three-year implementation study. This study will be used to inform future wide-spread implementation of PrEP.
- Drug Registration: The European Medicines Agency approved Truvada for PrEP in 2016. The EMA is responsible for the scientific evaluation of medicines developed by pharmaceutical companies for use in the European Union, but each member state will separately determine how, if at all, it might introduce PrEP.
- Policy/Regulatory: The National Health Service (NHS) is currently drafting recommendations for the criteria and clinical pathway for Truvada as PrEP. Data from mathematical models show that PrEP can be cost-effective for the NHS if it is specifically targeted. The earliest that PrEP could be made available by the NHS is mid- to late-2016.
- Advocacy: ACT UP London is a strong supporter of PrEP, organizing demonstrations in favor of access and vocal demand for PrEP is growing among gay men, with a strong local EATG presence. Also, check out prepster.info, a new PrEP website aimed to educate and agitate for PrEP access in England and beyond.
Last updated on September 1, 2017.